ZYUS Life Sciences Closes First Tranche of Downsized Private Placement

An announcement from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.

ZYUS Life Sciences has closed the first tranche of its downsized non-brokered private placement, issuing 451,269 units at C$0.63 each to raise approximately C$284,300. Each unit includes one common share and a half warrant exercisable at C$0.85 for 24 months, with proceeds earmarked for general corporate and working capital purposes.

The total unit offering has been revised from up to C$7 million to up to C$1.1 million, reflecting a more modest capital raise than originally planned. The financing, conducted under prospectus exemptions and subject to final TSX Venture Exchange approval, is intended to support ZYUS’s ongoing operations as it advances its non-opioid pain management drug candidates through clinical development.

The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.

More about ZYUS Life Sciences

ZYUS Life Sciences Corporation is a Saskatoon-based, clinical-stage life sciences company listed on the TSX Venture Exchange under the ticker ZYUS. The company focuses on developing and commercializing novel non-opioid pharmaceutical drug candidates for pain management, seeking to build a portfolio of protected intellectual property and achieve regulatory approvals for its therapies.

Average Trading Volume: 7,633

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$45.64M

For a thorough assessment of ZYUS stock, go to TipRanks’ Stock Analysis page.